The FDA found no evidence to confirm that orlistat was the cause of the reported liver injuries. However, Alli and Xenical labels were revised because of the reports. Talk to your doctor immediately if you have signs or symptoms that may indicate liver injury:. Orlistat the active ingredient in Alli promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines. Lipase, an enzyme found in the digestive tract, helps break down dietary fat into smaller components, so it can be used or stored for energy.
Orlistat inhibits the work of lipase. When you take the drug with a meal, about 25 percent of the fat you consume isn't broken down and is eliminated through bowel movements. Alli may help you lose weight, but the weight loss will likely be modest — perhaps just a few pounds more than you would lose with diet and exercise alone.
More than 40 percent of people taking Alli while following a calorie-restricted diet and increasing physical activity lost 5 percent or more of their body weight within a year.
Clinically meaningful weight loss — enough weight loss to begin lowering the risk of cardiovascular disease, diabetes and other diseases — is generally defined as 5 percent or more of body weight. People who ate a calorie-restricted diet, exercised regularly and took Alli lost an average of 5.
One milligram Alli pill is taken within an hour of a fat-containing meal up to three times a day. Daily fat intake should be distributed over the three main meals and should be no more than 30 percent of total calories. The manufacturer recommends a fat intake of about 15 grams a meal. If you eat a meal that contains no fat, then you don't need a dose of Alli.
If you take Alli with a high-fat meal, you will likely experience more-severe gastrointestinal side effects. Alli can reduce the absorption of fat-soluble nutrients, including beta carotene and vitamins A, D, E and K. Take a multivitamin at bedtime and at least two hours after your last dose of Alli. The active ingredient in Alli, orlistat, causes gastrointestinal side effects related to undigested fats passing through your digestive system.
They generally subside over time and with appropriate use of the medication. These side effects include:. Before taking Alli, talk with your doctor about possible interactions with other medications, particularly if you take medications for any of the following conditions:. A weight-loss plan with diet, exercise and drug therapy is generally considered successful if you lose about 1 pound 0. If the treatment is successful, you are more likely to keep weight off or lose more weight if you continue with the diet, exercise and drug treatment plan.
Most weight loss with the medication occurs within the first few months. If you have adhered to the diet and exercise plan and have not lost at least 5 percent of your initial body weight within a few months, continuing the medication may be of little benefit. If you haven't lost 5 percent of your body weight within a year on the plan, discontinuing the drug would be a reasonable choice. Orlistat is the only UK licensed medication that is clinically proven to reduce weight loss.
However, it is not as simple as taking the capsules and then seeing instant results. Orlistat does work, but in order for it to be effective, you must be committed to reducing your weight by adopting a healthy diet and adhering to a suitable exercise program.
Or browse all treatments or conditions. Dr Don Grant is The Independent Pharmacy's original online prescriber and has advanced in his role to become the Clinical Advisor, using his wealth of experience to advise on our clinical polices and prescribing guidelines.
What is Orlistat? Orlistat can be bought online today with a prescription. All you need to do is complete a short health consultation and get your treatment delivered as soon as the next day.
Related Guides Weight Loss. Written by Andy Boysan Published 3 Aug Weight Loss. Written by Andy Boysan Published 17 Jul Find more guides. Need something else? We stock treatments for 72 conditions. Search for a condition or treatment. Authored by. Reviewed by. Committee for Proprietary Medicinal Products opinion following an article 31 referral: Sibutramine. Effect of orlistat on cardiovascular disease risk in obese adults.
Diabetes Obes Metab ; 7 : — Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev ; 6 : — Download references. R Padwal originated the idea for this study and wrote the initial draft. All authors contributed to the study design, interpretation of the data, and critical revision of intermediate and final drafts.
A Kezouh performed the statistical analysis, with input from other authors. R Padwal had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis.
The opinions expressed herein represent the views of the authors and not the agencies that provided data. This project was not supported by any external funding source and was approved by the ethics panel at the University of Alberta. You can also search for this author in PubMed Google Scholar. Correspondence to R Padwal.
Note: This paper was presented as an oral presentation at the International Congress of Obesity in Sydney, Australia in September Reprints and Permissions. Padwal, R. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes 31, — Download citation. Received : 18 September Revised : 03 December Accepted : 26 February Published : 10 April Issue Date : October Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Trials Current Diabetes Reports International Journal of Obesity Drug Safety Advanced search.
Skip to main content Thank you for visiting nature. Download PDF. Abstract Objective: Orlistat and sibutramine are widely prescribed antiobesity agents that are approved for 2 years of continuous use. Design, setting and patients: Population-based administrative data from British Columbia, Canada, were used to create an inception cohort of orlistat and sibutramine users and determine the 2-year persistence with therapy.
Main outcome measure: Persistence with therapy at 2 years. Conclusion: This population-based, retrospective cohort analysis demonstrated very poor long-term persistence rates with orlistat and sibutramine and discontinuation rates that were much higher than those reported in clinical trials.
You have full access to this article via your institution. Main Antiobesity drugs are commonly used and generate hundreds of million dollars in annual sales. Methods Data sources The approximately four million residents of BC are serviced by a publicly funded health-care system, where eligible individuals may freely access hospital and physician services. Cohort assembly A priori , we decided to analyze persistence rates with orlistat and sibutramine in separate cohorts.
Table 1 Baseline demographics for each cohort Full size table. Figure 1. Kaplan—Meier llots demonstrating long-term persistence with orlistat and sibutramine. Full size image. References 1 Farrigan C, Pang K. Article Google Scholar 21 Wooltorton E. Acknowledgements R Padwal originated the idea for this study and wrote the initial draft.
View author publications.
0コメント